Among 14 evaluable patients (those with ≥ 2 tumor response assessments) receiving HB-200 plus pembrolizumab, the overall response rate was 43% (1 complete, 5 partial, all confirmed) and the disease control rate was 71%....Preliminary data with HB-200 arenavirus-based immunotherapy plus pembrolizumab demonstrate a favorable safety profile and preliminary efficacy when given as a 1L treatment of patients with R/M HPV16+ PD-L1+ HNSCC.